Compound profile

BPC-157

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

The most widely sold compound on the research market, and for that reason the one where documentation matters most.

What it is

BPC-157 is a synthetic pentadecapeptide of fifteen amino acids, derived from a sequence found in gastric protein. It is short, well established on the market, and comparatively straightforward to synthesise.

That last point drives everything about how it is priced and how it is counterfeited.

What does the research on BPC-157 actually show?

As of August 2026 there is no completed, published, placebo-controlled human trial of BPC-157 for any indication. The evidence base is almost entirely rodent work from a small number of laboratories, and a 2025 review in Current Reviews in Musculoskeletal Medicine concluded that the gap between that animal literature and clinical use remains unbridged.

BPC-157 is a synthetic pentadecapeptide of fifteen amino acids, said to be derived from a sequence found in human gastric juice. The nearest thing to a human programme is PL 14736, the same pentadecapeptide developed by a pharmaceutical sponsor for inflammatory bowel disease. That programme entered clinical trials and did not produce an approved product.

StudyWhat it isStatus, August 2026
PL 14736 (IBD programme)Same pentadecapeptide, pharmaceutical developmentEntered clinical trials; no approval, no published Phase 3
NCT02637284 (PCO-02)Safety and pharmacokineticsRegistered; status listed as unknown, no results posted
NCT07437547Acute hamstring muscle strain repairRecruiting. The first registered musculoskeletal trial
Rodent literatureTendon, muscle, gut, vascular modelsExtensive, largely single-group, no independent replication at scale
Human clinical record for BPC-157, checked against ClinicalTrials.gov and PubMed, August 2026.

Why the animal results do not settle the question

The BPC-157 animal literature reports healing effects across an unusually wide range of tissues and injury models. Breadth of that kind is a reason for caution as much as for interest: it concentrates in a narrow set of research groups, dosing is often intraperitoneal at levels that do not translate directly to human use, and independent replication is thin. None of that makes the findings wrong. It does mean they are hypotheses awaiting a controlled human test, and one has finally started recruiting.

What this evidence does not cover

BPC-157 is not an approved medicine anywhere. It was nominated as a bulk substance for pharmacy compounding in the United States and that nomination was withdrawn; the FDA records the substance as one that “may pose risk for immunogenicity for certain routes”.

No human dose is established. The doses circulating on forums are extrapolated from rodent studies by body-weight conversion. No trial has validated any of them for safety or effect.

Long-term safety is unmeasured. BPC-157 has angiogenic activity in animal models. What that means over months of use in humans has not been studied, and it is the reason most reviews stop short of endorsement.

Primary sources

What it costs, and why that is the problem

BPC-157 typically lists around $34.99 for a 5 mg vial. Set that against a general benchmark for custom synthesis of a twenty-amino-acid peptide, which runs to roughly $200, and the economics of the catalogue market become obvious.

A compound this cheap and this popular attracts volume selling, and volume selling attracts under-filled vials and substituted material. The saving available from cutting corners is small per vial but large across a catalogue.

Watch how shipping is structured too. Free-shipping thresholds around $150 are common and quietly push buyers toward larger orders than they need, which means committing more money to a single unverified batch.

What to check on the documentation

Because the sequence is short and cheap, purity documentation alone is weak protection: the realistic failure mode is not an impure vial but an under-filled or substituted one. Look for the stated mass to be supported by the certificate, and for the batch number on the document to match the batch on sale.

Be especially careful with combination products. BPC-157 is often sold pre-blended with TB-500. One aggregate purity figure across a blend cannot show that each component is present at the stated mass and individually pure.

Nothing on this page is medical advice, dosing guidance, or a recommendation to use any compound. These are research chemicals and are not approved for human use. See our medical disclaimer and editorial policy.

Our BPC-157 analysis

The BPC-157 dosage calculator handles the reconstitution arithmetic, and the BPC-157 TB-500 dosage calculator covers Wolverine blend vials, splitting each draw into its two compounds.

Reconstitution calculator

Work out the concentration and the units on the syringe from what is printed on your vial. Arithmetic only — it does not recommend a dose. More on how it works.

Enter what is printed on your vial and the dose you intend to use. This tool does the arithmetic only. It does not recommend doses, frequencies or schedules.

mg
mL

A starting point for the maths. Replace it with the amount you actually added.

Peptide Insider indexes vendor documentation and price. We do not sell peptides and we do not advise on their use. Nothing here is medical advice.